Académique Documents
Professionnel Documents
Culture Documents
ON
PROTEIN AND PEPTIDE DRUG DELIVERY
By
M.NAGESHWAR RAO,
M. Pharmacy , I YEAR II SEM
CONTENTS
Structure of protein.
Classification of protein.
Marketed formulations .
Conclusion.
References.
2
INTRODUCTION
PROTEINS : Proteins are the large organic compounds
STRUCTURE OF PROTEIN
There are four types.
Primary structure- The amino acid sequence.
Secondary
structure-
structures stabilized by
Regularly
repeating
local
hydrogen bond.
structure of
polypeptide
Quaternary
structure-The
structure
formed
by
Classification of
Proteins
According to their biological roles
Transport
proteinsi.e.
Haemoglobin
of
erythrocytes
Contractile or Motile proteins- i.e. Actin and
Myosin
Structural proteins- i.e. Collagen in bones
in biological cells.
Lack of proteins and peptides causes diseases
like Diabetes mellitus.
Diabetes mellitus is caused due to the lack of
protein called INSULIN.
Now a days R-DNA technology and hybridoma
techniques also used in protein and peptide
based pharmaceuticals.
7
drops.
Systemic absorption is extremely rapid.
Avoid first-pass metabolism.
The formulation can be designed to prolong
drug action and/or reduce drug concentrations to
achieve consistent drug action with least side
effects.
Drug delivery can be controlled precisely.
10
Stability problems:
(in vivo in the body)
very quickly
Unwanted allergic reactions may develop
(even toxicity)
Loss due to insolubility/adsorption
11
12
Excipients
Function
Example
Surfactants
Prevent denaturation
and aggregation
Antiaggregatory
Stabilize protein
against denaturation
Polysorbate 20, 80
Albumin
Sugars
Cryoprotectants
24 Jan. 2010
Stabilize protein
against very cold
condition
Modern College of Pharmacy, Pune
Serum albumin
Mannitol,
propylene glycol,
Sucrose, Lactose
Sugars, Amino
acids, Amines,
polyols, Salts
13
membranes:
Achieved by two mechanisms
1) Tran cellular: Enhancers increases
trancellular permeability of proteins and
peptide drugs by affecting membrane lipids
and proteins.
Various enhancers used in this pathway:
Dimethyl maleate
NSAID
MONOGLYSERIDES
14
15
D r u g D e li v e r y
R o u te o f A d m in is t r a ti o n
P u l m o n a ry
P a re n te ra l
T ra n sd e rm a l
I m p la n ts
D r u g M o d i f ic a ti o n
M is c e ll a n e o u s
O c u la r
O ra l
P E G y la t io n
P ro -d ru g
P o ly m e r d e p o t
N asal
16
17
Pumps :
1) Implantable infusion pumps
2) Mechanical pumps
18
19
delivery system.
Characters of polymers:
It should be biodegradable.
It should be bio compatible.
And non-toxic.
Two types of polymers are used widely
1)natural polymers
2)synthetic polymers
20
Proteins:
1) Natural polymers: Collagen , hemoglobin and gelatin.
2) Synthetic polymers: mainly poly esters like PLA and
21
22
24
25
Pumps:
Pumps :
Types of pumps:
1) Implantable infusion pumps: Drug is implanted
Oral route:
Encapsulated peptides or proteins in amino
28
Rectal route:
Insulin is administered in rectal route.
Advantages:
Reduction in first pass metabolism.
Rapid systemic absorption.
Safe and convenient for neonates and infants.
Withdrawal of drug easy , incase of adverse
effects.
29
Nasal route:
Nasal mucosa allows the effective systemic absorption of
30
Pulmonary route :
Lungs are attractive site for protein drug
Buccal route:
Mucoadhesive dosage forms can be used for
buccal route.
Adsorption enhancers like salicylates or a
surfactant is used for protein and peptide delivery
through buccal route.
Example:
Oxytocin , vasoprocin , insulin, are reported to be
absorbed through buccal mucosa . And adhesive
gel, patches , tablets are used.
Insulin is absorbed through buccal mucosa in the
presence of sodium glycolate.
32
Transdermal route:
For transdermal delivery of drugs is followed
Ocular route:
In this route enkephalins , thyrotrophin
34
Formulation aspects:
Storage:
Refrigeration
Packaging
Additives
Freeze-Drying
35
Protein Formulations
1
36
PEGylation
PEG is a non-toxic, hydrophilic, FDA
approved, uncharged polymer
Increases in vivo half life
Decreases immunogenicity
Increases protease resistance
Increases stability
37
Proteinylation
Attachment of additional or secondary
(nonimmunogenic) proteins for in vivo protection
Cross-linking with Serum Albumin
increases in vivo half life
Cross-linking or connecting by protein
engineering with antibody fragments
38
Formulation with
permeabilizers
Salicylates (aspirin)
Fatty acids
Metal chelators (EDTA)
39
Marketed formulations
Product
Formulation
Route
Indication
Lupron
Sterilized lyophilized
microspheres Contains
Leuprolide acetate.
i.m
Prostatic
cancer
Pitressin tannate
Vasopressin tannate in
peanut oil.
i.m
Antidiuretic
Adrenocorticotropic harmone
in gelatin
i.m. , s.c.
Endocrine
cancer
Sandostatin-l
depot
Octreotide
i.m.
Neurotropin
Growth harmone
i.m .
Drowsiness
Conclusion :
Protein and peptide based pharmaceuticals are
41
Reference:
Robinson, R. Joseph. Controlled Drug
42
Thank
you
43